Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular domain II of HER2, which results in ligand-dependent HER2–HER3 dimerization, leading to ADCC.

The nature of HER2 dimerization can vary significantly across different cancer types. In breast cancer, HER2 frequently forms heterodimers with HER3, and the HER2/HER3 heterodimer is highly potent ...

Advertising Feature: Application Note Published: April 2009 Visualizing signal transduction pathways by quantifying protein-protein interactions in native cells and tissue Simon Fredriksson Nature ...

Our ADC portfolio includes first-in-class or best-in-class candidates: Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and ...

TOKYO & BASKING RIDGE, N.J., June 09, 2025--DESTINY-Endometrial01 Ph. 3 Trial of ENHERTU Initiated as 1L Therapy in Patients w/ HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer ...

The de-escalation of therapy helps avoid unnecessary toxicity from treatment, making it an important consideration during the treatment of patients with brain cancer or metastases, Dr. Manmeet Singh ...

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get ...

HER2 mutations have also been identified as potential oncogenic drivers in lung cancer and occur in up to 4% of NSCLC. 2,3 In the past two decades, several clinical trials have investigated the ...

Updates in metastatic NSCLC from ASCO 2025 include data from TROPION-Lung02 on Dato-DXd, KRYSTAL-7 on first-line adagrasib, and zipalertinib from REZILIENT1, presented by Dr Jonathan Goldman.

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...